tiprankstipranks
XORTX Therapeutics Inc (XRTX)
NASDAQ:XRTX

XORTX Therapeutics Inc (XRTX) Stock Price & Analysis

33 Followers

XRTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.98 - $8.02
Previous Close$3.6
Volume27.31K
Average Volume (3M)66.81K
Market Cap
$7.17M
Enterprise Value$3.45M
Total Cash (Recent Filing)C$5.07M
Total Debt (Recent Filing)C$28.51K
Price to Earnings (P/E)-0.9
Beta0.68
May 01, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-3.79
Shares Outstanding1,998,848
10 Day Avg. Volume120,042
30 Day Avg. Volume66,806
Standard Deviation0.34
R-Squared0.00660
Alpha0.00322
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside279.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

XRTX FAQ

What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.98 and its highest was $8.02 in the past 12 months.
    What is XORTX Therapeutics Inc’s market cap?
    Currently, no data Available
    When is XORTX Therapeutics Inc’s upcoming earnings report date?
    XORTX Therapeutics Inc’s upcoming earnings report date is May 01, 2024 which is in 33 days.
      How were XORTX Therapeutics Inc’s earnings last quarter?
      XORTX Therapeutics Inc released its earnings results on Nov 14, 2023. The company reported -$0.676 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.676.
        Is XORTX Therapeutics Inc overvalued?
        According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does XORTX Therapeutics Inc pay dividends?
          XORTX Therapeutics Inc does not currently pay dividends.
          What is XORTX Therapeutics Inc’s EPS estimate?
          XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does XORTX Therapeutics Inc have?
          XORTX Therapeutics Inc has 1,998,848 shares outstanding.
            What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
            XORTX Therapeutics Inc reported an EPS of -$0.676 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.859%.
              Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
              Currently, no hedge funds are holding shares in XRTX
              ---

              Company Description

              XORTX Therapeutics Inc

              XORTX Therapeutics Inc is focused on developing drug therapies for orphan disease like polycystic kidney disease, and treatment of health consequences caused by chronic high serum uric acid which include cardiovascular disease and diabetes.
              ---

              XRTX Stock 12 Months Forecast

              Average Price Target

              $14.05
              ▲(279.67% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","8":"$8","15":"$15","4.5":"$4.5","11.5":"$11.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.0467890015915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$14.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.0477860842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$14.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.0467890015915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$14.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.5,8,11.5,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.274,4.1026760770455,4.931352154091,5.7600282311365,6.588704308182001,7.417380385227501,8.246056462273,9.0747325393185,9.903408616364,10.7320846934095,11.560760770455001,12.389436847500502,13.218112924546002,{"y":14.0467890015915,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.274,4.1027527757076925,4.931505551415385,5.760258327123077,6.589011102830769,7.417763878538461,8.246516654246154,9.075269429953845,9.904022205661539,10.732774981369232,11.561527757076924,12.390280532784615,13.219033308492307,{"y":14.0477860842,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.274,4.1026760770455,4.931352154091,5.7600282311365,6.588704308182001,7.417380385227501,8.246056462273,9.0747325393185,9.903408616364,10.7320846934095,11.560760770455001,12.389436847500502,13.218112924546002,{"y":14.0467890015915,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.185,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.171,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.48,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.841,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.715,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.21,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.31,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.837,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.33,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.2,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.76,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.274,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              XORTX Therapeutics Inc
              Tetra Bio-Pharma

              Best Analysts Covering XRTX

              1 Year
              James MolloyAlliance Global Partners
              1 Year Success Rate
              1/2 ratings generated profit
              50%
              1 Year Average Return
              -12.25%
              reiterated a buy rating 3 months ago
              Copying James Molloy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -12.25% per trade.
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis